Search Results
Your search for ,New matches 16922 pages
Showing 701 - 750AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...
Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), accepted the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine...
AACR 2025: Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid ...
AACR 2025: Novel Targeted Therapy Under Study in Selected Patients With Advanced Solid Tumors
The first-in-class covalent Werner helicase inhibitor (RO7589831) demonstrated early signals of efficacy as well as general tolerability in patients with advanced solid tumors harboring certain genetic defects, according to results from a phase I trial. Agents in this class target the DNA repair...
AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer
The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation, according to the preliminary results of the early-phase Beamion LUNG-1 trial. These findings were...
AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors
PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient (dMMR) cancers, according to preliminary results from a phase II trial presented at the 2025 American Association...
Addition of Neoadjuvant/Adjuvant Pembrolizumab Significantly Improves Outcomes in Locally Advanced HNSCC
The addition of neoadjuvant and adjuvant pembrolizumab to standard-of-care therapy significantly improved event-free survival over the standard of care alone for patients with locally advanced head and neck cancer in the phase III KEYNOTE-689 trial, according to results presented at the American...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
WHI Funding Future Unclear
Women’s Health Initiative (WHI) investigators were informed on April 21 that the Department of Health and Human Services (HHS) will terminate WHI Regional Center (RC) contracts at the end of the current fiscal year (September 2025). The WHI Clinical Coordinating Center (CCC) will continue...
Case 3: Patient With Recurrent Chromophobe RCC
This is Part 3 of New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel George, Michael Harrison, and Catherine Fahey discuss the treatment of recurrent ...
Case 2: Patient With Recurrent Clear Cell RCC
This is Part 2 of New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel George, Michael Harrison, and Catherine Fahey discuss the treatment of recurrent ...
Case 1: Patient With Poor-Risk Metastatic RCC
This is Part 1 of New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel George, Michael Harrison, and Catherine Fahey discuss the treatment of a patient ...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Use of Investigational Tool to Detect Advanced-Stage Invasive Cervical Cancer
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
SGO’s President-Elect Brings Professional Experience and Passion to Her New Role
Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cancer Center in Tampa, Florida, brings many years of professional experience and active SGO membership...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study Details In...
Response to Immune Checkpoint Inhibitors Not Affected by Age
Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...
Role of Pathologists in Improving Access to Safer, More Effective Allogeneic Cell Therapies
Researchers are working to accelerate the clinical adoption of novel allogeneic cell therapies to improve cancer care and treatment, according to a new report from the College of American Pathologists (CAP). Background Allogeneic cell therapy—which uses cells from a healthy donor rather than a...
Updated CAP Guideline Aims to Address Rising Rates of HPV-Associated Squamous Cell Carcinomas
The College of American Pathologists (CAP) updated its testing guideline to capture new research and emerging technologies to improve the diagnostic accuracy of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinomas, according to a guideline update published by Lewis et al in...
CAP Issues New and Updated Cancer Protocols
New protocols for endocrine tumors and updated existing protocols for breast cancer diagnoses are now available from the College of American Pathologists (CAP). These and other updates to protocols reflect the latest scientific advancements, ensuring that pathology reports provide oncologists with...
Early-Life Exposure to Environmental Carcinogens May Increase Risk of Pediatric Papillary Thyroid Cancer
Perinatal and early-life exposure to ambient fine particulate matter air pollution (PM2.5) and outdoor artificial light at night (O-ALAN) may be associated with a statistically significant increased risk of papillary thyroid cancer in children and young adults up to 19 years old, according to the...
Metabolic Syndrome May Increase Risk of Cancer Recurrence, Subsequent Mortality Among Breast Cancer Survivors
Breast cancer survivors with metabolic syndrome may have an elevated likelihood of breast cancer recurrence and subsequent breast cancer–related mortality, according to new findings to be presented by Harborg et al at the European Congress on Obesity (ECO) 2025, taking place between May 11 and 14...
Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, FASCO, to Lead Women’s Cancers Program at City of Hope
Hope S. Rugo, MD, FASCO, recently joined the staff of City of Hope as the new Director of the Women’s Cancers Program, Division Chief of Breast Medical Oncology, and Professor in the Department of Medical Oncology and Therapeutics Research. In her role, she will lead and enhance City of Hope’s...
Germline Variants May Impact Unique Nature of a Patient’s Cancer, Study Shows
Research into germline genetic variants has identified ways that an individual’s genetic makeup can shape the biology of their cancer. The report, published in Cell, shows how these findings could potentially be applied to future treatment strategies to make cancer treatment more personalized. A...
Can ctDNA Monitoring Help to Predict Melanoma Recurrence?
A new study showed that approximately 80% of patients with stage III melanoma who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence. Researchers also found that the disease returned more than four times...
Parasitic Infection and Its Treatment Linked to Cancer-Related Gene Activity in the Cervix
New research has revealed that Schistosoma haematobium, a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment. Presented at ESCMID Global 2025, this pivotal study sheds new light ...
Novel Drug/Device Combination May Improve Outcomes in Metastatic Uveal Melanoma
Percutaneous hepatic perfusion using a melphalan hepatic delivery system (melphalan/HDS) may be an effective treatment option in patients with unresectable uveal melanoma that has metastasized to the liver, according to a recent study published by Zager et al in the Annals of Surgical Oncology....
ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma
Investigators have identified a key component inhibiting responses to lenalidomide in patients with multiple myeloma, according to the results of a study recently published in Blood. They identified adenosine deaminase acting on RNA1 (ADAR1) as a novel driver of acquired resistance to lenalidomide...
Most Pediatric Cancer Deaths Occur in Regions of Conflict
Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology. Investigators from St. Jude Children’s Research Hospital, Duke University, and other institutions sought to reveal the relationship between...
Ideal Apixaban Dose for Cancer-Associated VTE
In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer. Study Details In the double-blind...
Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples
A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
American Cancer Society Launches CEO Search
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) announced the launch of a nationwide search to find the organizations’ next Chief Executive Officer (CEO). In November, the ACS Board of Directors appointed Wayne A.I. Frederick, MD, MBA, to serve as...
Preclinical Study Finds FGFR2 Inhibition May Prevent Some KRAS-Expressing Pancreatic Cancers
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is also among the most deadly, with an average 5-year survival rate of less than 10%. The malignancy is often preceded by precancerous lesions. Traditional treatments of the cancer, including chemotherapy, surgery, and...
Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer
In an analysis from the phase III MIRASOL trial reported in The Lancet Oncology, Van Gorp et al found no significant difference in quality of life between patients receiving mirvetuximab soravtansine vs chemotherapy for folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer. In...
Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings
Many patients who are eligible for lung cancer screening do not receive it, but do receive preventative screenings for other cancer types, according to the results of a new study published by Potter et al in JAMA. Background Although lung cancer screening is recommended for certain individuals...
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior...
Grocery Store Choice Could Impact Obesity-Related Cancer Mortality
A novel tool could help elucidate consumer behaviors at the county level as well as the relationship between the location where individuals shopped for their food and their risk of obesity-related cancer mortality, according to a recent study published by Lin et al in BMC Medicine. Background Over...
Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in...
Is Surgery Necessary to Treat Invasive Breast Cancer?
Surgery may not be necessary for patients with early-stage breast cancer who had a complete response to neoadjuvant chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center. Five-year results from the phase II...
Local Excision May Be Feasible in Patients With Low Rectal Adenocarcinoma
Chemotherapy followed by local excision may be effective in patients with node-negative low rectal adenocarcinoma, according to new findings presented by Buettner et al at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. Background The current standard of care among most patients with...
AI Integration in Global Programs of CT Screening for Lung Cancer and Other Tobacco-Related Illnesses
A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE), has proposed a public health program of longitudinal chest computed tomography (CT) screenings among a global high-risk population of tobacco-exposed individuals utilizing...
Accelerated Onset of Aging-Related Diseases in Childhood Cancer Survivors?
In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases. Study Details The study focused on data from the Childhood Cancer Survivor Study and national databases...
